Zeo ScientifiX, Inc. Annual Report Summary

This summary offers a clear look at Zeo ScientifiX, Inc.'s past year, drawing directly from their annual report. We aim to cut through technical jargon, helping you understand the company's operations, current standing, and what it might mean for your investment decisions.

1. Business Overview (What the Company Does)

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. This means they develop new medicines, but their products are still undergoing testing in clinical trials and are not yet available for widespread use. This stage typically involves significant research and development costs, high risk, and no current revenue from product sales. Future success heavily depends on trial outcomes and regulatory approvals. The company's primary mission is to create innovative biological treatments for degenerative diseases (conditions that worsen over time) and regenerative medicine (treatments that repair or replace damaged tissues).

Zeo develops products using unique components derived from ethically sourced birth tissue, including mesenchymal stem cells, exosomes, and Wharton's Jelly matrix. This approach harnesses natural biological processes for healing and regeneration.

Their two main product candidates are:

• Zofin™: Derived from amniotic fluid, this product retains natural components like extracellular vesicles, proteins, and cell nanoparticles.
• Patient Pure X™ (PPX™): A personalized treatment developed from a patient's own blood, containing a specialized fraction of nanoparticles.

Zeo manufactures all its products in FDA-registered and cGMP-compliant facilities, ensuring adherence to strict quality standards set by the U.S. Food and Drug Administration.

For the fiscal year ending October 31, 2025, the market value of common stock held by non-affiliate investors was approximately $7.13 million as of April 30, 2025, based on a closing share price of $2.05. As of January 28, 2026, 7,614,941 shares of common stock were outstanding. The company is classified as a "smaller reporting company" and a "non-accelerated filer." This means it has less complex reporting requirements than larger companies. For investors, this can imply less public information, potentially less analyst coverage, and often indicates an earlier-stage company.

2. Risk Factors (Key Risks)

The company acknowledges several broad categories of risks that could impact its actual results and stock price. These include:

• The actual advantages and effectiveness of their products.
• Their ability to achieve future growth.
• The sufficiency of their cash resources for operations and expansion.
• Compliance with regulatory requirements for manufacturing and sales.
• Obtaining necessary regulatory approvals (e.g., from the FDA).
• The market opportunities for their product candidates.
• The outcomes and success rates of their clinical trials.
• Their competitive position against other companies.
• Their adaptability to market changes.
• Their ability to protect their intellectual property (IP).

3. Future Outlook (Guidance, Strategy)

The company generally expresses expectations for future growth and aims to secure sufficient cash to fund its operations and expansion. Their focus also includes achieving regulatory approvals for their products and protecting their intellectual property.